6640--Intent to Sole Source: Diasorin Liaison XL Cost Per Test | SAM.gov Opportunity | G2X

6640--Intent to Sole Source: Diasorin Liaison XL Cost Per Test

Solicitation36C26121Q1015Notice typeSolicitation

Attachments

1 file

Name	Type	Posted	Actions
36C26121Q1015_1.docx	DOCX	Aug 23, 2021	Download

Version History

6640--Intent to Sole Source: Diasorin Liaison XL Cost Per Test

Solicitation36C26121Q1015Aug 23, 2021 · v5

LatestViewing

Opportunity Summary

The Department of Veterans Affairs, Network Contracting Office 21, intends to establish a single-award fixed-price indefinite delivery/indefinite quantity contract with Diasorin Inc. for a five-year period of performance. This requirement provides Diasorin Liaison XL Analyzer Cost Per Test services to support testing for procalcitonin, vitamin D, Quantiferon TB, and COVID-19 at the VA Southern Nevada Health Care System in North Las Vegas, Nevada. Solicitation 36C26121Q1015 addresses repetitive laboratory needs using highly specialized, FDA-approved assays compatible with existing equipment already located on-site.

This procurement is classified under NAICS 334516, Analytical Laboratory Instrument Manufacturing, and PSC 6640, Laboratory Equipment and Supplies. The government’s intent to sole source is based on the determination that Diasorin Inc. is the only provider capable of meeting agency requirements. Specifically, the Liaison XL is the only open-access, continuous-feed instrument capable of detecting latent Tuberculosis using an FDA-cleared assay.

The response deadline for this notice is August 7, 2021, and the primary point of contact is Moneque L. Rodriguez. Documentation associated with this notice includes one attachment titled 36C26121Q1015_1.docx. If no alternative sources demonstrate the ability to comply with the requirements, the government will proceed with the sole-source acquisition and execute a Justification and Approval as required by federal regulation.

Generated by Lumen AI

Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.

Opportunity Summary

Opportunity Details

Response deadline: Aug 7, 2021Expired 1772 days ago
NAICS: 334516 (opens in new tab)
PSC: 6640 (opens in new tab)
Set aside: —
Published: Aug 23, 2021
Updated: Aug 23, 2021
Agency: VETERANS AFFAIRS, DEPARTMENT OF (opens in new tab)
Office: 261-NETWORK CONTRACT OFFICE 21 (36C261)
Department: —
Source: View on SAM.gov (opens in new tab)

Contact and place of performance

Point of contact: Moneque L Rodriguez

Place of performance: Not specified

Original Description

PRE-SOLICITATION NOTICE OF INTENT TO SOLE SOURCE Department of Veterans Affairs (VA) Network Contracting Office 21 (NCO 21) hereby gives notice of the Government s intent to establish a single award fixed price indefinite delivery/ indefinite quantity (IDIQ) contract for a period of performance of 5 years with Diasorin Inc. to acquire Diasorin Liaison XL Analyzer Cost Per Test (CPT) services to run procalcitonin, vitamin D, Quantiferon TB, and covid tests. This IDIQ will be used as a simplified method of filling anticipated repetitive needs at the VA Southern Nevada Health Care System: 6900 N Pecos Road, North Las Vegas, NV 89086. Determination of this single source procurement is in accordance with Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements per 41 U.S.C. 1901 and as implemented by FAR 13.106-1(b)(2). It is the Government s belief that the proposed candidate is the only provider of Diasorin Liaison XL Analyzer (CPRR) services that can meet the agency s needs. The applicable North American Industry Classification System (NAICS) code is 334516 (Analytical Laboratory Instrument Manufacturing) and the Federal Supply Code (FSC) is 6640 (Laboratory Equipment and Supplies). The Liaison XL Analyzer currently exists on site, and the supplies that are needed are highly specialized, FDA approved assays capable of being processed using CLIA technology and those fitting of all of laboratory s requirements. Diasorin s Liaison XL is the only open access, continuous feed instrument capable of detecting latent Tuberculosis using an FDA cleared assay. All responsible sources may submit a quotation, capability statement, and supporting evidence furnished in sufficient detail to demonstrate the ability to comply with the above requirement by August 06, 2021 at 3PM Hawaii Time to [email protected] to be considered. After this time if no alternative sources are found, a sole source solicitation will be posted to this announcement. After consideration, the Government will determine whether to proceed with the sole source acquisition. A Justification and Approval (J&A) will be executed by the Head of Contracting Activity (HCA) for the contract and will be posted to SAM.gov as required by the Federal Acquisition Regulation (FAR) 13.501 (a)(1)(iii).